December 8, 2021 | CHPT, Daily JAM, Morning Briefing, NKTR, Short Term |
With the VIX “fear index” falling back closer to “normal” levels–it dropped to 21.89 yesterday from 31.12 on December 1–it sure feels like the extreme volatility of the end of November and early December is on the ebb. The move to yesterday’s 21.89 close from December 1 was was a surge of 30% in the CBOE S&P 500 Volatility Index in a week. This move away from panic follows on a jump in the “fear index” in the week from November 24 to December 1 of 67% in the opposite direction. I’d be surprised if we don’t see another surge in volatility in the rest of December or in January with what promises to be a crazy earnings season, but even if volatility holds at something like today’s level–slightly elevated from the historical averages but in the rough ballpark–don’t forget that volatility has a long tail. Volatility, in fact, creates volatility. And not least of all in individual stocks.
February 1, 2021 | Daily JAM, Jubak Picks, NKTR, Stock Alerts |
Nektar (NKTR) is another one of those stocks that looks to be moving up more strongly right now than the relatively sparse news would explain. Shares of this biotech are up 18.96% in the last week and 24.37% for the last 3 months. I can see a stream of positive news that should be leading the stock gradually higher, but nothing that is especially “current.”
January 15, 2020 | Daily JAM, NKTR, Stock Alerts |
Yesterday an advisory joint committee at the U.S. Food & Drug Administration voted to reject Nektar's application for its new non-addictive opioid NKTR-181. The thinking--my thinking--was that the committee had structured the vote so that the most likely outcome...
January 13, 2020 | Daily JAM, NKTR, Stock Alerts, Volatility |
I understand why the U.S. Food & Drug Administration has moved so slowly on a decision on Nektar Therapeutic's (NKTR) new non-addictive opioid NKTR-181. The last thing the FDA wants to do in the midst of epidemic of opioid addiction is to approve a drug that might...
August 13, 2019 | Daily JAM, NKTR, Stock Alerts, Volatility |
What we know about Nektar Therapeutics (NKTR) is pretty clear. On Thursday of last week, August 8, trading in shares of Nektar were halted on news from the company had manufacturing problems that resulted in some patients enrolled in the clinical trials for the...
June 17, 2019 | Daily JAM, NKTR, PE, Stock Alerts |
Again. I'm adding the January 17, 2020 Call Options with a strike at $35 on Nektar Theraeutics (NKTR) to my Volatility Portfolio on JubakAM.com and JugglingWithKnives.com. (Ticker on these options is NKTR200117C00035000.) The underlying shares closed at $33.70, up...
June 12, 2019 | Daily JAM, NKTR, Stock Alerts |
Shares of Nektar Therapeutics (NKTR) have been bumping along between $32 and $34 for two months now, but the company continues to take steps to prepare for the likely August approval of NKTR-181, a new non-addictive opioid. Nektar has formed Inheris Biopharma, a...
April 4, 2019 | Daily JAM, NKTR, Stock Alerts |
Nektar Therapeutics (NKTR) won't miss Wall Street earnings projections when it reports its first quarter financial results on May 9--because the company won't report any earnings. The consensus projection now has the company reporting a loss of 76 cents a share on...
January 8, 2019 | Daily JAM, INCY, IONS, NKTR |
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday's close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big drug...
December 20, 2018 | AAPL, Daily JAM, EQNR, FCX, NKTR, PXD, Stock Alerts, VIX, Volatility |
In November and December I selectively added risk to my Volatility Portfolio in the expectation of a strong seasonal January Effect Rally and the odds of an end of the year bounce that would, temporarily, disrupt the developing bear market. I thought that was a...
October 8, 2018 | Daily JAM, NKTR, Stock Alerts |
The longs and the shorts continue to battle over Nektar Therapeutics (NKTR.) Right now the shorts have the best of that fight. No contest. The shares of this biotech fell another 1.24% today to close at $51.71. A little more than a month ago they were at $68.49. But I...
August 20, 2018 | Daily JAM, NKTR, Stock Alerts |
I'm on vacation through August 26. I'm trying to use this down time to catch up on earnings results that I missed during the very busy second quarter earning season. After the market close on Wednesday, August 8, Nectar Therapeutics (NKTR) reported earnings of $5.33 a...